Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $9.60 USD
Change Today -0.85 / -8.13%
Volume 23.6K
AEMDD On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

aethlon medical inc (AEMDD) Snapshot

Open
$10.38
Previous Close
$10.45
Day High
$10.38
Day Low
$9.50
52 Week High
11/24/14 - $36.00
52 Week Low
09/18/14 - $5.13
Market Cap
63.4M
Average Volume 10 Days
29.7K
EPS TTM
$-1.93
Shares Outstanding
6.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AETHLON MEDICAL INC (AEMDD)

Related News

No related news articles were found.

aethlon medical inc (AEMDD) Related Businessweek News

No Related Businessweek News Found

aethlon medical inc (AEMDD) Details

Aethlon Medical, Inc. operates as a medical device company, which focuses on creating devices for the treatment of cancer, infectious diseases, and other life-threatening conditions. It develops Aethlon Hemopurifier, a medical device that targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The company’s Aethlon Hemopurifier is intended for the treatment of antiviral drug-resistance in hepatitis-C virus and human immunodeficiency virus infected individuals; serves as a countermeasure against viral pathogens not addressed by drug or vaccine therapies; and represents the therapeutic strategy to address cancer promoting exosomes. It also develops exosome-based products to diagnose and monitor cancer, infectious diseases, and neurological disorders; and is developing a medical device to reduce the incidence of sepsis in combat-injured soldiers. The company was formerly known as Bishop Equities Inc and changed its name to Aethlon Medical, Inc. in March 2000. The company was founded in 1991 and is based in San Diego, California.

10 Employees
Last Reported Date: 01/30/15
Founded in 1991

aethlon medical inc (AEMDD) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $400.0K
President and Director
Total Annual Compensation: $240.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $183.0K
Chief Science Officer, Senior Vice President ...
Total Annual Compensation: $195.0K
Compensation as of Fiscal Year 2014.

aethlon medical inc (AEMDD) Key Developments

Aethlon Medical, Inc. will Change its Ticker to AEMDD from AEMD

Effective April 14, 2015, Aethlon Medical, Inc. will change its Pink Sheets LLC stock ticker symbol to AEMDD from AEMD.

Aethlon Medical, Inc. Announces Ebola Humanitarian Use Device Submission to the United States Food and Drug Administration

Aethlon Medical, Inc. announced that it has submitted a Humanitarian Use Device submission to the United States Food and Drug Administration to support potential market clearance of the Aethlon Hemopurifier as a treatment for Ebola virus. The Hemopurifier is a first-in-class bio-filtration device designed for the single-use removal of viruses and shed glycoproteins from the circulatory system of infected individuals. The device targets antiviral drug resistance and could serve as a first-line countermeasure against Ebola and other viruses that are not addressed with proven drug therapies. A Humanitarian Use Device is intended to benefit patients by treating or diagnosing a disease or condition that affects or is manifested in fewer than 4,000 individuals in the United States per year. If the HUD application is designated by the FDA, Aethlon may then submit a Humanitarian Device Exemption marketing application to the Center for Devices and Radiological Health for marketing review. There is no assurance that Aethlon will receive HDE approval to market the Hemopurifier as a treatment for Ebola virus.

Aethlon Medical, Inc. Announces First Patient Completes Hemopurifier Clinical Study Protocol

Aethlon Medical, Inc. announced that the first patient enrolled in the company's FDA approved feasibility study has completed their full Hemopurifier treatment protocol without any device-related adverse events. The study protocol, which is being administered at DaVita Med Center Dialysis in Houston, is enrolling ten chronic dialysis patients infected with Hepatitis C virus (HCV) to receive a six treatment protocol of Hemopurifier therapy. The feasibility study will contribute safety data to advance the Hemopurifier as a candidate therapy to address chronic conditions such as HIV and HCV, as well as acute bioterror and pandemic threats that are not addressed with proven drug or vaccine therapies.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AEMDD:US $9.60 USD -0.85

AEMDD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AEMDD.
View Industry Companies
 

Industry Analysis

AEMDD

Industry Average

Valuation AEMDD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 49.6x
Price/Book 56.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 51.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AETHLON MEDICAL INC, please visit www.aethlonmedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.